JP2016537383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537383A5 JP2016537383A5 JP2016532636A JP2016532636A JP2016537383A5 JP 2016537383 A5 JP2016537383 A5 JP 2016537383A5 JP 2016532636 A JP2016532636 A JP 2016532636A JP 2016532636 A JP2016532636 A JP 2016532636A JP 2016537383 A5 JP2016537383 A5 JP 2016537383A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- monoclonal antibody
- pharmaceutical composition
- cancer
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 108010062802 CD66 antigens Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 9
- 102000048362 human PDCD1 Human genes 0.000 claims 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 6
- 102000048119 human PDCD1LG2 Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 210000005168 endometrial cell Anatomy 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000055639 human CEACAM3 Human genes 0.000 claims 1
- 102000047627 human CEACAM5 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908190P | 2013-11-25 | 2013-11-25 | |
| US61/908,190 | 2013-11-25 | ||
| PCT/IL2014/051019 WO2015075725A1 (en) | 2013-11-25 | 2014-11-25 | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221240A Division JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537383A JP2016537383A (ja) | 2016-12-01 |
| JP2016537383A5 true JP2016537383A5 (enExample) | 2018-01-11 |
| JP6879739B2 JP6879739B2 (ja) | 2021-06-02 |
Family
ID=53179065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532636A Active JP6879739B2 (ja) | 2013-11-25 | 2014-11-25 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
| JP2019221240A Pending JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221240A Pending JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10081679B2 (enExample) |
| EP (2) | EP3763387B1 (enExample) |
| JP (2) | JP6879739B2 (enExample) |
| KR (1) | KR102362803B1 (enExample) |
| CN (1) | CN105744955B (enExample) |
| AU (1) | AU2014351308B2 (enExample) |
| CA (1) | CA2930218C (enExample) |
| ES (2) | ES2808684T3 (enExample) |
| HK (1) | HK1225998A1 (enExample) |
| MX (1) | MX375221B (enExample) |
| PL (2) | PL3763387T3 (enExample) |
| RU (1) | RU2697522C1 (enExample) |
| WO (1) | WO2015075725A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2922875T1 (sl) | 2012-11-20 | 2017-06-30 | Sanofi | Protitelesa anti-CEACAM5 in njihove uporabe |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| AP2016009504A0 (en) * | 2014-04-27 | 2016-10-31 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| CN107345969A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途 |
| US11220543B2 (en) * | 2016-11-14 | 2022-01-11 | Dinona | Antibody binding specifically to CD66c and use thereof |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| CN106957823A (zh) * | 2016-12-28 | 2017-07-18 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l2蛋白单克隆抗体及其用途 |
| KR102019913B1 (ko) * | 2017-03-24 | 2019-09-09 | 재단법인 목암생명과학연구소 | 항-ceacam1 항체 및 이의 용도 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| JP2022513729A (ja) * | 2018-12-07 | 2022-02-09 | ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
| EP3898694A4 (en) * | 2018-12-20 | 2023-02-15 | Albert Einstein College of Medicine | ANTAGONIST ANTIBODIES TO HUMAN IMMUNOBAL SCORE CEACAM1 (CD66A) AND FORMULATIONS, KITS AND METHODS OF USE THEREOF |
| KR102166982B1 (ko) * | 2019-01-24 | 2020-10-16 | 가톨릭대학교 산학협력단 | 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법 |
| BR112021017864A2 (pt) * | 2019-03-12 | 2021-12-07 | Harvard College | Métodos e composições para tratamento do câncer |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| IL302731A (en) | 2020-11-10 | 2023-07-01 | Sanofi Sa | Formulation of an antibody-drug conjugate for CEACAM5 |
| WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20250139898A (ko) * | 2022-11-10 | 2025-09-23 | 페임웨이브 리미티드 | 호중구 세포외 트랩 (net) 매개 활성 억제를 위한 항암배아항원 관련 세포 부착 분자 1 (ceacam1) 항체 |
| JP2025540021A (ja) * | 2022-12-07 | 2025-12-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | 抗ｃｄ２４抗体及びｐｄ－１－ｐｄ－ｌ１経路遮断抗体を使用した癌に対する併用療法 |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| KR20240113400A (ko) * | 2023-01-11 | 2024-07-22 | 한국과학기술원 | 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| CN121335923A (zh) * | 2023-04-13 | 2026-01-13 | 苏州逻晟生物医药有限公司 | Ceacam1靶向抗体及其用途 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| JP3490437B2 (ja) | 1992-01-23 | 2004-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 単量体および二量体抗体フラグメント融合タンパク質 |
| WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DE69633175T2 (de) | 1995-05-23 | 2005-08-11 | Morphosys Ag | Multimere proteine |
| JP4843138B2 (ja) | 1998-04-15 | 2011-12-21 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Ｔ細胞阻害性受容体組成物およびその使用 |
| ES2720160T3 (es) * | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| DE102008036127A1 (de) | 2008-08-01 | 2010-02-04 | Emitec Gesellschaft Für Emissionstechnologie Mbh | Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| AU2010225456B2 (en) * | 2009-03-18 | 2016-03-17 | Carina Biotech Pty Ltd | Biomarkers and uses thereof |
| PL2990421T3 (pl) * | 2009-04-30 | 2018-08-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| US20150273056A1 (en) * | 2012-10-12 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
-
2014
- 2014-11-25 MX MX2016006726A patent/MX375221B/es active IP Right Grant
- 2014-11-25 PL PL20151989.9T patent/PL3763387T3/pl unknown
- 2014-11-25 PL PL14863190T patent/PL3074035T3/pl unknown
- 2014-11-25 EP EP20151989.9A patent/EP3763387B1/en active Active
- 2014-11-25 KR KR1020167015560A patent/KR102362803B1/ko active Active
- 2014-11-25 AU AU2014351308A patent/AU2014351308B2/en not_active Ceased
- 2014-11-25 HK HK16114541.7A patent/HK1225998A1/zh unknown
- 2014-11-25 ES ES14863190T patent/ES2808684T3/es active Active
- 2014-11-25 WO PCT/IL2014/051019 patent/WO2015075725A1/en not_active Ceased
- 2014-11-25 CN CN201480062823.5A patent/CN105744955B/zh active Active
- 2014-11-25 ES ES20151989T patent/ES2980417T3/es active Active
- 2014-11-25 RU RU2016124540A patent/RU2697522C1/ru active
- 2014-11-25 CA CA2930218A patent/CA2930218C/en active Active
- 2014-11-25 US US15/039,022 patent/US10081679B2/en active Active
- 2014-11-25 EP EP14863190.6A patent/EP3074035B1/en active Active
- 2014-11-25 JP JP2016532636A patent/JP6879739B2/ja active Active
-
2019
- 2019-12-06 JP JP2019221240A patent/JP2020055853A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537383A5 (enExample) | ||
| JP2020055853A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2019524701A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2021054859A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017535257A5 (enExample) | ||
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| JP2018508483A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| JP2018505674A5 (enExample) | ||
| JP2019535670A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2013506428A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2014526898A5 (enExample) |